Public-registry trials using REGENECYTE that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
| Trial | Sponsor | Condition | Phase | Sites |
| Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome | StemCyte, Inc. | Long COVID | PHASE2 | 1 |
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →